OGI241220C4000
- 0.15
- 0.000.00%
OrganiGram Newsroom
CCORF Maintains OrganiGram(OGI.US) With Buy Rating, Raises Target Price to $2.62
Organigram Holdings Inc. Price Target Raised to C$3.60/Share From C$3.25 by Canaccord Genuity
OrganiGram Holdings Analyst Ratings
Canaccord Genuity Assumes OrganiGram Holdings at Speculative Buy, Announces Price Target of C$3.25
Analysts' Top Healthcare Picks: OrganiGram Holdings (OGI), Plus Therapeutics (PSTV)
OrganiGram Holdings Analyst Ratings
Alliance Global Partners Upgrades OrganiGram Holdings to Buy, Announces C$4.25 Price Target
Analysts Are Bullish on These Healthcare Stocks: Tonix Pharma (TNXP), OrganiGram Holdings (OGI)
Organigram Holdings (TSE:OGI) Plunges With Plans to Enter US Market
Buy Rating Affirmed for OrganiGram Holdings Amid Strong Profit Margins and Strategic Market Positioning
Jefferies Reaffirms Their Buy Rating on OrganiGram Holdings (OGI)
Analysts Offer Insights on Healthcare Companies: OrganiGram Holdings (OGI), Camurus AB (OtherCAMRF) and CSL (OtherCMXHF)
OrganiGram Holdings (OGI) Receives a Buy From Jefferies
OrganiGram Holdings (OGI) Receives a Buy From Jefferies
Jefferies Reaffirms Their Buy Rating on OrganiGram Holdings (OGI)
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), OrganiGram Holdings (OGI) and Passage Bio (PASG)
OrganiGram Holdings: A Strong Buy on Impressive Domestic Growth and Market Traction
Stifel Maintains Buy on OrganiGram Holdings, Raises Price Target to $4
OrganiGram Holdings Analyst Ratings
Organigram Holdings Maintained at Buy at Stifel GMP Following Q2 Results; Price Target Raised to C$4.00